Plasbumin-25 (albumin human)

Dosage of albumin human is variable and should be individualized based on the specific indication, concentration of albumin human solution used, and clinical status and response of the patient. The manufacturers' information should be consulted for specific dosage recommendations.

Predetermined formulas for dosage calculation generally are avoided since they assume that the same dose is appropriate for all patients. In the absence of active hemorrhage, total daily albumin dosage should not exceed the theoretical amount present in normal plasma volume (i.e., 2 g/kg body weight).

Response to therapy should be determined by factors such as hemodynamic response (e.g., blood pressure), degree of pulmonary congestion, and hematocrit. Serum protein concentrations usually do not need to be monitored during albumin human therapy, but may be useful in some cases of hypoproteinemia to estimate the total body albumin deficit and guide selection of dosage.

Osmotic Equivalence of Commercially Available Albumin Human Injections for IV Infusion

Albumin human injection for IV Osmotic equivalence infusion 100 mL of 5% solution (5 g) 100 mL of normal human plasma 100 mL of 20% solution (20 g) 400 mL of normal human plasma 100 mL of 25% solution (25 g) 500 mL of normal human plasma

Albumin human solutions are administered by IV infusion.

The concentration of albumin human administered (i.e., albumin human 5, 20, or 25% solution) depends on the fluid and protein requirements of the patient and is determined in part by whether there is a greater need for volume or oncotic replacement.

Albumin human 5% solutions usually are preferred in the treatment of acute blood volume deficits in the absence of adequate or excessive hydration.

Albumin human 20 or 25% solutions may be preferred when there is an oncotic deficit or when hypovolemia is long standing (e.g., due to treatment delay) and hypoalbuminemia exists in the presence of adequate or excessive hydration. Albumin human 20 or 25% solutions also are preferred when the drug is being used for its binding rather than oncotic effects (e.g., in the treatment of neonatal hyperbilirubinemia).

When used for the treatment of hypovolemia, albumin human solutions are most effective in well-hydrated patients. If the patient is dehydrated, albumin human 5% solution usually is preferred; if albumin human 20 or 25% solutions are used in dehydrated patients, additional crystalloids or other fluids should be administered.

No dosing information is available for this tab.

No dosing information is available for this tab.

Specific drug interaction studies have not been performed using albumin human.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Animal reproduction studies have not been performed with albumin human. It is not known whether albumin human can cause fetal harm when administered during pregnancy or during labor or delivery. Potential risks and benefits for the specific patient should be considered, and albumin human should be used in pregnant women or during labor and delivery only if clearly needed. One manufacturer states that there is no evidence for any contraindications specifically associated with reproduction, pregnancy, or the fetus.

It is not known whether albumin human is distributed into milk. Albumin human should be used with caution in breast-feeding women and only when clearly needed.

No enhanced messaging available.